-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Incoming block pain is caused by partial or complete abnormalities in the nerves passed in around or in the center.
most common are post-herpes nerve pain and central pain.
mechanism is unclear and may be related to increased sensitivity of the central nervous system and the expansion of pain-feeling areas and their lower thresholds.
LX9211 is an effective, oral delivery of the selective AAK1 small molecule inhibitor.
pharmaceutical company Lexicon identified AAK1 as a target for the treatment of nerve pain.
LX9211 has been "fast-tracked" by the U.S. Food and Drug Administration (FDA) for the treatment of nerve pain around diabetes.
Lexicon recently announced that it has begun a randomized, placebo-controlled, multi-center Phase II clinical trial (RELIEF-PHN 1 study) for the treatment of nerve pain after herpes.
Praveen Tyle, executive vice president of research and development at
Lexicon, said: "Herpes patients typically continue to experience persistent pain for months to years after the rash is removed, and treatment is currently limited.
believe that LX9211 has the potential to offer new treatments for post-herpes nerve pain."
RELIEF-PHN 1 study was designed to assess the efficacy, safety, and pharmacodynamics of LX9211 in nerve pain after shingles treatment.
the study will recruit about 74 patients from about 30 clinical centers.
。
